stockportfolio.pro
Structure Therapeutics Inc. (GPCR)
Healthcare · Biotechnology · NasdaqGM
Structure Therapeutics Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-51.32M | $-89.62M | $-122.53M | $-141.20M |
| Net margin | — | — | — | — |
Source: Structure Therapeutics Inc. SEC filings (10-K).
Explore 4 years of Structure Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GPCR in your portfolio →
Structure Therapeutics Inc. financial history by metric
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Structure Therapeutics Inc. — frequently asked questions
What is Structure Therapeutics Inc.'s revenue?
Structure Therapeutics Inc. (GPCR) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Structure Therapeutics Inc. profitable?
No — GPCR reported a net loss of $-141.20M in fiscal 2025.
What is GPCR's P/E ratio?
Structure Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Structure Therapeutics Inc. have?
As of fiscal year 2025, GPCR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Structure Therapeutics Inc.'s market cap?
Structure Therapeutics Inc. (GPCR) has a market capitalization of about $3.01B, based on the latest data in our nightly-refreshed cache.
When does Structure Therapeutics Inc.'s fiscal year end?
GPCR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Structure Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.